FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1387-1388 March 29, 2007 Number 13

PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kahn, S. E.

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy . Having discovered an error in their original reporting, the authors undertook a complete audit of all the data reported in the published article. The results of that audit change some of the published data, as follows. None of these changes materially affect the scientific findings, interpretation, or conclusions of the study. In the Methods section, the last sentence under Study Design (page 2428) should have read "Patients were followed until the termination of the study in June 2006, with a median treatment duration of 4.0 years (maximum, 6.1)," rather than "(maximum, 6.0)." In Table 1 (page 2430), in the "Time since diagnosis of diabetes" entry, the number of rosiglitazone patients should have been 651 for <1 year and 758 for 1–2 years. In the Results section, the first sentence under Secondary Outcomes (page 2433) should have read "The rate of progression to a confirmed fasting plasma glucose level of more than 140 mg per deciliter also differed significantly among the groups: 79 of 511 patients in the rosiglitazone group, as compared with 127 of 520 patients in the metformin group (risk reduction, 36%; 95% CI, 15 to 52; P=0.002)," rather than "risk reduction, 34%." In Figure 3 (page 2434), the ranges should have been as follows: Age: 50 yr, >50–60 yr, >60 yr; BMI: 30, >30–35, >35; Weight: 82.0 kg, >82.0–97.3 kg, >97.3 kg; Waist circumference: 99 cm, >99–110 cm, >110 cm; and Baseline fasting plasma glucose: 140 mg/dl, >140 mg/dl. The third sentence of the third paragraph under Secondary Outcomes (page 2434) should have read "From the longitudinal linear model, a mean glycated hemoglobin level of less than 7% was maintained until the visit at 57 months in the rosiglitazone group" rather than "60 months." In Figure 4A (page 2436), the Treatment difference (95% CI) for rosiglitazone vs. metformin should have been –9.8 (–12.6 to –7.0). In Figure 4G (page 2437), the Annualized slope (95% CI) should have been –0.12 (–0.32 to 0.07) for metformin and 0.12 (–0.10 to 0.34) for glyburide. In Figure 4H (page 2437), the Annualized slope (95% CI) should have been 0.0010 (–0.0006 to 0.0026) for metformin and 0.0011 (–0.0007 to 0.0029) for glyburide. In the Discussion section, the third sentence of the second paragraph (page 2439) should have read "By comparing three drugs head to head, our study provides long-term evidence that progressive loss of glycemic control can be delayed and a mean level of glycated hemoglobin maintained at less than 7% for a longer period with rosiglitazone (57 months)" rather than "60 months." The second sentence of the fifth paragraph in the same section (page 2440) should have read "The protocol specified that all patients be free of known CHF on entry into the study. However, a retrospective review of source documents revealed that 17 patients (5 in the rosiglitazone group, 6 in the metformin group, and 6 in the glyburide group) entered the study with a current diagnosis of CHF. Only one of these patients (randomized to metformin) contributed to the events of CHF that are detailed in Table 2" rather than "At study entry, all patients were free of known CHF." The article has been corrected on the Journal's Web site at www.nejm.org.

PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kahn, S. E.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.